US20230218541A1 - Enhanced Moisturizing Lotion Compositions - Google Patents
Enhanced Moisturizing Lotion Compositions Download PDFInfo
- Publication number
- US20230218541A1 US20230218541A1 US18/122,555 US202318122555A US2023218541A1 US 20230218541 A1 US20230218541 A1 US 20230218541A1 US 202318122555 A US202318122555 A US 202318122555A US 2023218541 A1 US2023218541 A1 US 2023218541A1
- Authority
- US
- United States
- Prior art keywords
- moisturizing lotion
- lotion composition
- concentration
- extract
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003020 moisturizing effect Effects 0.000 title claims abstract description 213
- 239000000203 mixture Substances 0.000 title claims abstract description 210
- 239000006210 lotion Substances 0.000 title claims abstract description 207
- 239000000284 extract Substances 0.000 claims abstract description 91
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 72
- 244000042664 Matricaria chamomilla Species 0.000 claims abstract description 39
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims abstract description 39
- 244000144927 Aloe barbadensis Species 0.000 claims abstract description 26
- 235000002961 Aloe barbadensis Nutrition 0.000 claims abstract description 26
- 235000011399 aloe vera Nutrition 0.000 claims abstract description 26
- 241000124033 Salix Species 0.000 claims abstract description 18
- 240000001519 Verbena officinalis Species 0.000 claims abstract description 17
- 235000018718 Verbena officinalis Nutrition 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229930000044 secondary metabolite Natural products 0.000 claims description 52
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 33
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 20
- 229940101267 panthenol Drugs 0.000 claims description 20
- 235000020957 pantothenol Nutrition 0.000 claims description 20
- 239000011619 pantothenol Substances 0.000 claims description 20
- 241000195493 Cryptophyta Species 0.000 claims description 14
- 239000010478 argan oil Substances 0.000 claims description 14
- 239000004599 antimicrobial Substances 0.000 claims description 13
- 239000008367 deionised water Substances 0.000 claims description 6
- 229940099451 3-iodo-2-propynylbutylcarbamate Drugs 0.000 claims description 4
- WYVVKGNFXHOCQV-UHFFFAOYSA-N 3-iodoprop-2-yn-1-yl butylcarbamate Chemical compound CCCCNC(=O)OCC#CI WYVVKGNFXHOCQV-UHFFFAOYSA-N 0.000 claims description 4
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 claims description 4
- 229960001083 diazolidinylurea Drugs 0.000 claims description 4
- 210000003491 skin Anatomy 0.000 description 80
- 230000000845 anti-microbial effect Effects 0.000 description 25
- 208000002193 Pain Diseases 0.000 description 22
- 235000019441 ethanol Nutrition 0.000 description 20
- 239000003795 chemical substances by application Substances 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 17
- 230000008901 benefit Effects 0.000 description 16
- 238000011282 treatment Methods 0.000 description 16
- 201000004624 Dermatitis Diseases 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 12
- 241001135917 Vitellaria paradoxa Species 0.000 description 11
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 229940057910 shea butter Drugs 0.000 description 10
- 230000000844 anti-bacterial effect Effects 0.000 description 9
- 208000010668 atopic eczema Diseases 0.000 description 9
- 230000004888 barrier function Effects 0.000 description 9
- 239000003974 emollient agent Substances 0.000 description 9
- 230000000202 analgesic effect Effects 0.000 description 8
- 239000003963 antioxidant agent Substances 0.000 description 8
- 230000003750 conditioning effect Effects 0.000 description 8
- 229940119170 jojoba wax Drugs 0.000 description 8
- 230000036556 skin irritation Effects 0.000 description 8
- 206010040880 Skin irritation Diseases 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 231100000475 skin irritation Toxicity 0.000 description 7
- 239000004094 surface-active agent Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 6
- 229960000541 cetyl alcohol Drugs 0.000 description 6
- 230000002500 effect on skin Effects 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- 235000021419 vinegar Nutrition 0.000 description 6
- 239000000052 vinegar Substances 0.000 description 6
- 229920002907 Guar gum Polymers 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 229940121363 anti-inflammatory agent Drugs 0.000 description 5
- 239000002260 anti-inflammatory agent Substances 0.000 description 5
- 229940121375 antifungal agent Drugs 0.000 description 5
- 239000007844 bleaching agent Substances 0.000 description 5
- 229920006317 cationic polymer Polymers 0.000 description 5
- 239000000665 guar gum Substances 0.000 description 5
- 235000010417 guar gum Nutrition 0.000 description 5
- 229960002154 guar gum Drugs 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 230000007794 irritation Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000037317 transdermal delivery Effects 0.000 description 5
- -1 without limitation Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 4
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 4
- 206010063562 Radiation skin injury Diseases 0.000 description 4
- 206010000496 acne Diseases 0.000 description 4
- 230000000843 anti-fungal effect Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000001153 anti-wrinkle effect Effects 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 125000002091 cationic group Chemical group 0.000 description 4
- 239000003906 humectant Substances 0.000 description 4
- 230000036571 hydration Effects 0.000 description 4
- 238000006703 hydration reaction Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 201000001119 neuropathy Diseases 0.000 description 4
- 230000007823 neuropathy Effects 0.000 description 4
- 208000033808 peripheral neuropathy Diseases 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 241001678559 COVID-19 virus Species 0.000 description 3
- 241000711573 Coronaviridae Species 0.000 description 3
- 208000007514 Herpes zoster Diseases 0.000 description 3
- 244000309467 Human Coronavirus Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 241000315672 SARS coronavirus Species 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 229940049294 glyceryl stearate se Drugs 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 229940068977 polysorbate 20 Drugs 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- 230000037307 sensitive skin Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- BWDWHFVTDDCJOY-UHFFFAOYSA-L 2-hydroxyethyl-[2-hydroxy-3-[2-hydroxyethyl(dimethyl)azaniumyl]propyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].OCC[N+](C)(C)CC(O)C[N+](C)(C)CCO BWDWHFVTDDCJOY-UHFFFAOYSA-L 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000025721 COVID-19 Diseases 0.000 description 2
- 241000192700 Cyanobacteria Species 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000199919 Phaeophyceae Species 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 241000206572 Rhodophyta Species 0.000 description 2
- 241001278079 Salix nigra Species 0.000 description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 2
- 206010040830 Skin discomfort Diseases 0.000 description 2
- 239000005708 Sodium hypochlorite Substances 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940064004 antiseptic throat preparations Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 229940124447 delivery agent Drugs 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 229960002870 gabapentin Drugs 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical class 0.000 description 2
- 229940013585 hydroxypropyl bis-hydroxyethyldimonium chloride Drugs 0.000 description 2
- 238000005461 lubrication Methods 0.000 description 2
- 210000004324 lymphatic system Anatomy 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000036572 transepidermal water loss Effects 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
- DYOWGCNNYMLFQV-UHFFFAOYSA-N 2-acetyloxybenzoic acid;2-hydroxybenzamide;1,3,7-trimethylpurine-2,6-dione Chemical compound NC(=O)C1=CC=CC=C1O.CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C DYOWGCNNYMLFQV-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010014201 Eczema nummular Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 206010033433 Pain in jaw Diseases 0.000 description 1
- 241000282372 Panthera onca Species 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 241000646858 Salix arbusculoides Species 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010041955 Stasis dermatitis Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 241000159243 Toxicodendron radicans Species 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000001140 aloe barbadensis leaf extract Substances 0.000 description 1
- 235000014104 aloe vera supplement Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229960002842 clobetasol Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- USZAGAREISWJDP-UHFFFAOYSA-N crisaborole Chemical compound C=1C=C2B(O)OCC2=CC=1OC1=CC=C(C#N)C=C1 USZAGAREISWJDP-UHFFFAOYSA-N 0.000 description 1
- 229950008199 crisaborole Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002249 decongestive effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229940114930 potassium stearate Drugs 0.000 description 1
- ANBFRLKBEIFNQU-UHFFFAOYSA-M potassium;octadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCCCC([O-])=O ANBFRLKBEIFNQU-UHFFFAOYSA-M 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229940108442 valtrex Drugs 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/76—Salicaceae (Willow family), e.g. poplar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/88—Two- or multipart kits
- A61K2800/884—Sequential application
Definitions
- Embodiments disclosed herein relate generally to topical moisturizing lotions. More specifically, embodiments disclosed herein relate to topical moisturizing lotions for treating skin irritation, inflammation, and discomfort.
- An embodiment of a moisturizing lotion composition comprises water, propylene glycol having a concentration of 21.0 to 37.5 wt % of the moisturizing lotion composition,
- aloe vera having a concentration of 0.50 to 4.0 wt % of the moisturizing lotion composition
- vervain extract having a concentration of 0.50 to 4.0 wt % of the moisturizing lotion composition
- willow bark extract having a concentration of 0.50 to 0.20 wt % of the moisturizing lotion composition
- chamomilla recutita extract having a concentration of 0.05 to 0.40 wt % of the moisturizing lotion composition, wherein a ratio of the concentration of the propylene glycol to the concentration of the chamomilla recutita extract is between 4.5 and 5.5.
- the moisturizing lotion comprises argan oil having a concentration of 0.02 to 0.30 wt % of the moisturizing lotion composition.
- the moisturizing lotion comprises an algae extract having a concentration of 1.5 to 3.0 wt % of the moisturizing lotion composition.
- the moisturizing lotion comprises panthenol having a concentration of 0.25 to 2.0 wt % of the moisturizing lotion composition.
- the water is de-ionized water having a concentration of 40 to 85 wt % of the moisturizing lotion composition.
- the concentration of the propylene glycol is 22.5 wt % to 31.3 wt %.
- the concentration of the aloe vera is 0.9 to 1.25 wt %. In certain embodiments, the concentration of the chamomilla recutita extract is 0.09 to 0.13 wt % of the moisturizing lotion composition. In certain embodiments, a ratio of the concentration of the aloe vera to the concentration of the vervain extract is between 0.90 and 1.10. In certain embodiments, the moisturizing lotion comprises a secondary compound including alcohol having a concentration of 40 to 100 wt % of the secondary compound.
- An embodiment of a moisturizing lotion composition comprises de-ionized water, propylene glycol having a concentration of 12.5 to 50.0 wt % of the moisturizing lotion composition, aloe vera having a concentration of 0.5 to 2.0 wt % of the moisturizing lotion composition, vervain extract having a concentration of 0.50 to 4.0 wt % of the moisturizing lotion composition, chamomilla recutita extract having a concentration of 0.07 to 1.5 wt % of the moisturizing lotion composition, and panthenol having a concentration of 0.25 to 2.0 wt % of the moisturizing lotion composition, and willow bark extract having a concentration of 0.09 to 0.13 wt % of the moisturizing lotion composition, wherein a ratio of the concentration of the propylene glycol to the concentration of the chamomilla recutita extract is between 4.5 and 5.5, wherein a ratio of the concentration of the propylene glycol to the concentration of the panthenol is
- the moisturizing lotion comprises an antimicrobial compound.
- the antimicrobial compound comprises diazolidinyl urea having a concentration of 0.14 to 0.55 wt % of the moisturizing lotion composition, or iodopropynyl butylcarbamate having a concentration 0.01 to 0.05 wt % of the moisturizing lotion composition.
- the moisturizing lotion comprises a secondary compound including alcohol having a concentration of 40 to 100 wt % of the secondary compound.
- a ratio of the concentration of the chamomilla recutita extract to the concentration of the willow bark extract is between 0.80 and 1.20.
- the moisturizing lotion comprises argan oil having a concentration of 0.04 to 0.07 wt % of the moisturizing lotion composition, wherein a ratio of the concentration of the Chamomilla recutita extract to the concentration of the argan oil is between 1.5 and 2.5. In some embodiments, a ratio of the concentration of the panthenol to the concentration of the chamomilla recutita extract is between 4.0 and 6.0.
- Embodiments described herein comprise a combination of features and characteristics intended to address various shortcomings associated with certain prior compositions and methods.
- the foregoing has outlined rather broadly the features and technical characteristics of the disclosed embodiments in order that the detailed description that follows may be better understood.
- the various characteristics and features described above, as well as others, will be readily apparent to those skilled in the art upon reading the following detailed description and examples. It should be appreciated that the conception and the specific embodiments disclosed may be readily utilized as a basis for modifying or designing other compositions and methods for carrying out the same purposes as the disclosed embodiments. It should also be realized that such equivalent constructions do not depart from the spirit and scope of the principles disclosed herein.
- applying may include any method of introducing a composition or substance into contact with the skin, such as by being rubbed, poured, sprinkled, sprayed, or combinations thereof.
- a “cosmetic use” includes any use intended to improve the aesthetic appearance of the skin, such as by cleansing, beautifying, promoting attractiveness, or combinations thereof.
- a cosmetic benefit is typically visual or aesthetic, and can be evaluated using subjective and/or objective assays known in the art.
- a “dermopharmaceutical use” includes uses intended for the treatment, mitigation or prevention of a disease or disorder of the skin, and/or intended to affect the structure or a function of the skin.
- a dermopharmaceutical use typically has a physiological, pharmacological, and/or therapeutic effect on the skin.
- a dermopharmaceutical use may result in an improved aesthetic appearance of the skin by virtue of its physiological, pharmacological, or therapeutic effects.
- a dermopharmaceutical benefit can be evaluated using subjective and/or objective assays known in the art.
- an “antimicrobial use” is a use that targets, kills, inactivates, or slows the growth of microorganisms, and thus is defined broadly herein to include antibiotic uses, antibacterial uses, antiviral uses, and antiseptics uses.
- antibiotic uses are those that target and/or kill bacteria, fungi, parasites, or combinations thereof.
- Antibacterial uses are those that target and/or kill bacterial cells, and may rely on a bacteriocidal that deteriorates the integrity of cell walls and/or a bacteriostatic that inhibits the growth and/or reproduction of bacterial cells.
- Antiviral uses are those that kill viruses, inhibit the growth of viruses, or otherwise target viruses.
- Antiseptics are substances typically used on bodily tissues (e.g., skin) to reduce the possibility of infections, sepsis, or putrefaction, and are generally distinguished from antibiotics, which are internally transportable via the lymphatic system within the body.
- antimicrobial uses may include the use of compounds usable outside of the body only (e.g., on the face or hands), uses within the body (e.g., within the nasal passages, mucous membranes), and uses that may or may not involve compounds transportable via the lymphatic system.
- coronaviruses are a group of related viruses defined broadly to include, for example: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), cause of Coronavirus Disease 2019 (COVID-19); Severe Acute Respiratory Syndrome virus (SARS-CoV), cause of Severe Acute Respiratory Syndrome (SARS); and Middle East Respiratory Syndrome Coronavirus (MERS-CoV), cause of the Middle East Respiratory Syndrome (MERS), and Human Coronaviruses (HCoVs)].
- SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2
- SARS-CoV Severe Acute Respiratory Syndrome virus
- SARS Severe Acute Respiratory Syndrome virus
- SARS-CoV Severe Acute Respiratory Syndrome virus
- MERS-CoV Middle East Respiratory Syndrome Coronavirus
- MERS Middle East Respiratory Syndrome Coronavirus
- coronaviruses including SARS-CoV-2, SARS-CoV, MERS-CoV, and HCoVs can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days, but can be efficiently inactivated within one minute in response to contact with surface disinfectant comprising, for example, 62% to 71% ethanol, 0.5% hydrogen peroxide or 0.1% sodium hypochlorite, as described for example in Persistence of Coronaviruses on Inanimate Surfaces and Their Inactivation With Biocidal Agents by G. Manuel et al. Journal of Hospital Infection, Volume 104, Issue 3, March 2020, Pages 246-251, which is hereby incorporated herein by reference in its entirety.
- surface disinfectant comprising, for example, 62% to 71% ethanol, 0.5% hydrogen peroxide or 0.1% sodium hypochlorite
- a “dermal delivery” refers to a process of mass transport of active ingredients applied on the skin to various skin strata.
- a “transdermal delivery” refers to the entire process of mass transport of substances applied on the skin surface and includes their absorption by each skin strata, the strata's uptake by microcirculation, and the further distribution in the outer systemic circulation to at least a minor degree.
- the term “antimicrobial” refers to an agent that kills or prohibits the growth of microorganisms such as bacteria, fungals, viruses, and parasites.
- antimicrobials include antibacterials (e.g., bactericides), antivirals, antiparasitics, and antifungals.
- compositions and methods for using same as disclosed herein may be used for cosmetic uses, dermopharmaceutical uses, antimicrobial uses, or combinations thereof.
- Such compositions may generally be referred to herein as “moisturizing lotion compositions,” which can be used to treat the skin, protect the skin, improve the condition of the skin, improve the aesthetic appearance of skin, or combinations thereof.
- compositions disclosed herein may be suitable for use on skin to moisturize, hydrate, reduce inflammation, reduce irritation, reduce pain, or combinations thereof.
- properties of embodiments of moisturizing lotion compositions disclosed herein may be particularly beneficial for treating eczema, psoriasis, rosacea, or dermatitis including: contact dermatitis, photo dermatitis, seborrheic dermatitis, nummular dermatitis, stasis dermatitis, dermatitis herpetiformis, atopic dermatitis, and allergic dermatitis.
- the moisturizing lotion compositions disclosed herein is suitable for treating diabetic neuropathy and reducing nerve pain of the skin.
- some embodiments of compositions disclosed herein contain combinations of compounds that exhibit analgesic (e.g., pain relieving) benefits that are enhanced by a dermal or transdermal delivery behavior of the compositions, which offers the potential to increase the degree of pain relief and/or reduce the time to achieve such pain relief.
- analgesic e.g., pain relieving
- the onset of pain relief following application of embodiments of moisturizing lotions described herein resulted in less than 5 minutes of application.
- compositions disclosed herein offer the potential to reduce sagging, reduce scarring, reduce age spots, reduce wrinkles, or combinations thereof.
- some embodiments of compositions disclosed herein may be beneficial for treating skin damage and/or irritation associated with chafing, sunburn, sensitive skin, dry skin, rough skin, flaky skin, red skin, irritated skin, and itchy skin.
- the anti-inflammatory properties of embodiments disclosed herein may improve acne, blisters, rash, or hives.
- moisturizing lotion compositions include a plurality of compounds or ingredients that are uniformly and homogeneously blended together to offer potential for synergistic benefits in treating the skin. More specifically, embodiments of moisturizing lotion compositions disclosed herein include one or more of the following: skin conditioning agent(s), aloe vera, algae extract, vervain extract, an anti-inflammatory agent, cationic polymer(s), film forming barrier(s), emollient(s), cationic low humidity humectant(s), willow bark extract, antifungal and/or antibacterial compound(s), cetyl alcohol, surfactant(s) and/or emulsion agent(s), anti-wrinkle agent(s), alpha hydroxyl acid(s), lipid(s) and/or monoglyceride(s), and anti-oxidant agent(s).
- skin conditioning agent(s) aloe vera, algae extract, vervain extract, an anti-inflammatory agent, cationic polymer(s), film forming barrier(s), emolli
- Embodiments of the moisturizing lotion composition can include a variety of types of skin conditioning agents including, without limitation, propylene glycol.
- the propylene glycol has a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 12.5 wt % to about 40.0 wt %, alternatively ranging from about 18.7 wt % to about 37.5 wt % of the moisturizing lotion composition, alternatively ranging from about 21.0 wt % to 37.5 wt % of the moisturizing lotion composition, and alternatively from about 22.5% to about 31.3% wt % of the moisturizing lotion composition.
- the skin conditioning agent e.g., propylene glycol
- the Chamomilla recutita extract has a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 0.05 wt % to about 0.40 wt %, alternatively ranging from about 0.07 wt % to about 0.15 wt %, and alternatively ranging from about 0.09 wt % to about 0.13 wt %.
- Chamomilla recutita extract functions as a skin conditioning agent by moisturizing the skin and restoring suppleness.
- chamomilla recutita extract is an antioxidant that protects skin from free-radical damage.
- Chamomilla recutita extract also provides antiseptic and anti-inflammatory properties. Such properties can aid in fading spots on the skin, eliminating scars, and treating acne.
- chamomilla recutita extract can provide analgesic (e.g., pain relieving) benefits as described in Clinical Evaluation of Fluid Extract of Chamomilla recutita for Oral Aphthae, M. Ramos et al., Journal of Drugs Dermatol. 2006; 5(7):612-617, which is hereby incorporated herein by reference in its entirety.
- flavinoids in chamomilla recutita extract can sooth and calm the skin, and offer the potential to improve the speed at which damaged skin heals.
- chamomilla recutita extract may be particularly beneficial in treating dry skin, eczema, psoriasis, and skin irritation.
- Chamomilla recutita extract may also be particularly beneficial for with particularly sensitive skin as it is anti-irritating, non-comedogenic, and hypoallergenic.
- the chamomilla recutita extract may work in combination with the panthenol, aloe vera, and salicylic acid to further sooth skin irritation and further increase the antimicrobial efficacy of such secondary compounds.
- Embodiments of the moisturizing lotion composition can include aloe vera such as aloe barbadensis, aloe barbadensis leaf juice, aloe vera gel, aloe vera extract, or combinations thereof.
- the aloe vera has a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 0.50 wt % to about 4.00 wt %, alternatively ranging from about 0.75 wt % to about 1.50 wt %, and alternatively ranging from about 0.90 wt % to about 1.25 wt %.
- the aloe vera is an anti-inflammatory and provides analgesic (i.e., pain relieving) effects.
- the aloe vera also provides skin calming (soothing and cooling), moisturizing, and anti-wrinkle properties. Consequently, aloe vera may be particularly beneficial for treating burns, eczema, and related irritation and pain. Such benefits may be enhanced by improved dermal and/or transdermal delivery properties of the moisturizing lotion composition.
- the aloe vera may sooth or otherwise mitigate skin irritation, thereby allowing higher concentrations of antimicrobial agents to be applied to sensitive skin areas as compared to skin that has not been treated with the moisturizing lotion composition.
- application of the moisturizing lotion composition may enable hand sanitizers with higher concentrations of alcohol to be applied to skin, face, or nasal passages when the moisturizing lotion composition is applied to such areas in combination with the sanitizer (e.g., before, simultaneous with, or after application of the sanitizer).
- the aloe vera prolong the period of time the skin can be exposed to such secondary compounds.
- the enhancements to the antimicrobial efficacy of such secondary compounds provided by aloe vera may be two-fold, as the short term effectiveness may be increased by the higher concentrations of antimicrobial agents (e.g. alcohol, etc.), and the long term effectiveness may be increased as the antimicrobial agents may remain on the skin for a longer period of time.
- antimicrobial agents e.g. alcohol, etc.
- Embodiments of the moisturizing lotion composition can include algae extract derived or extracted from a variety of sources including, without limitation, freshwater algae species such as green algae, red algae, brown algae, or combinations thereof; seaweed; marine algae (e.g., kelp extracts such as alginate); cyanobacteria or “blue-green algae;” and combinations thereof.
- freshwater algae species such as green algae, red algae, brown algae, or combinations thereof
- seaweed e.g., kelp extracts such as alginate
- cyanobacteria or “blue-green algae;” and combinations thereof cyanobacteria or “blue-green algae;” and combinations thereof.
- red or brown algae extract are particularly preferred.
- the algae extract has a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 1.0 wt % to 8.0 wt %, alternatively ranging from about 1.5 wt % to about 3.0 wt %, and alternatively ranging from about 1.8 wt % to about 2.5 wt %.
- the algae extract functions as an antioxidant, moisturizes the skin, normalizes the moisture content of the skin, and provides suppleness, which can result in anti-aging characteristics.
- the algae extract provides lubrication and hydration to the skin.
- Algae extract is a non-irritating and noncomedogenic. Accordingly, embodiments of the moisturizing lotion compositions including algae extract offer the potential to provide improved modes and rates for hydration and lubrication, as well as delivery of other ingredients of the moisturizing lotion composition into the epidermis.
- the algae extract may also provide analgesic (e.g., pain relieving) benefits and/or facilitate analgesic benefits provided by other constituents of the moisturizing lotion composition.
- Embodiments of the moisturizing lotion composition can include vervain extract.
- the vervain extract included in the moisturizing lotion composition has a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 0.50 wt % to about 4.00 wt %, alternatively ranging from about 0.75 wt % to about 1.50 wt %, and alternatively ranging from about 0.90 wt % to about 1.25 wt %.
- Vervain extract is an anti-oxidant, which may work in synergy with essential derivatives to beneficially scavenge free radicals.
- the vervain extract may also enhance prostaglandins, which stimulates extracellular transmission of the active ingredients of the moisturizing lotion composition.
- vervain extract may provide analgesic (e.g., pain relieving) benefits, as well as function as a skin conditioning agent with emollient properties.
- vervain extract is also believed to stimulate circulation as an arterial vasodilator and as a decongestive on vein flow, which may enhance the rate of dispersion of one or more of the ingredients of the moisturizing lotion composition and/or enhance the rate of pain relief.
- Embodiments of the moisturizing lotion composition can include one or more anti-inflammatory agents including, without limitation, panthenol.
- the panthenol has a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 0.25 wt % to about 2.00 wt %, alternatively ranging from about 0.37 wt % to about 0.75 wt %, and alternatively ranging from about 0.45 wt % to about 0.63 wt %.
- the anti-inflamatory agent(s) such as panthenol offer the potential to reduce redness and irritation of the skin, while also supplementing the moisturizing and lubricity of the moisturizing lotion composition.
- panthenol may work together and synergistically with the aloe vera to further sooth skin irritation and further increase the antimicrobial efficacy of such secondary compounds.
- Embodiments of the moisturizing lotion composition can include one or more cationic polymers such as guar gum, guar gum modified with hydroxyalkyl groups, guar gum modified with hydroxypropyl groups, or combinations thereof.
- Guar gum is commercially available as Jaguar® available from Rhodia.
- the hydroxyalkyl groups may include alkyl groups with any number of carbon atoms.
- the cationic polymer(s) e.g., guar gum
- the cationic polymer(s) have a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 0.17 wt % to about 0.70 wt %, alternatively ranging from about 0.26 wt % to about 0.53 wt %, and alternatively ranging from about 0.31 wt % to about 0.44 wt %.
- concentration expressed as a wt % of the moisturizing lotion composition
- Such cationic polymers offer the potential to provide protection against disruptions of the cell surface by surfactants.
- Embodiments of the moisturizing lotion composition can include one or more film forming barriers such as jojoba oil.
- the jojoba oil has a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 0.05 wt % to about 0.20 wt %, alternatively ranging from about 0.07 wt % to about 0.15 wt %, and alternatively ranging from about 0.09 wt % to about 0.13 wt %.
- Film barriers such as jojoba oil offer the potential to limit moisture transfer from or through the skin. More particularly, jojoba oil may limit transepidermal water loss from the skin.
- jojoba oil may act as an emollient and/or be used to regulate the viscosity of the moisturizing lotion composition.
- the film forming barriers may include argan oil in addition to or as an alternative to jojoba oil.
- the argan oil has a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 0.02 wt % to about 0.30 wt %, alternatively ranging from about 0.03 wt % to about 0.08 wt %, and alternatively ranging from about 0.04 wt % to about 0.07 wt %.
- the one or more film forming layers such as jojoba oil and argan oil form a barrier layer or residue layer adjacent or proximal the skin, while one or more other compounds within the moisturizing lotion composition remain suspended above the skin in an aqueous or semi-aqueous state. Consequently, in embodiments where the moisturizing lotion composition is used to enhance the antimicrobial efficacy of one or more secondary compound(s) applied to the skin, the residue layer may form a physical barrier that reduces contact between the skin and the one or more secondary compound(s).
- argan oil may also act as an anti-wrinkle agent. Based on some testing, it is believed that argan oil alone or via a synergistic effect when used in combination with chamomilla recutita extract may provide an enhanced analgesic (e.g., pain relieving) benefit.
- Embodiments of the moisturizing lotion composition can include an emollient such as butyrospermum parkii (shea butter) or shea butter based esters.
- the emollient e.g., the shea butter or shea butter based esters
- the concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 0.02 wt % to about 0.10 wt %, alternatively ranging from about 0.03 wt % to about 0.08 wt %, and alternatively ranging from about 0.04 wt % to about 0.07 wt %.
- a shea butter based ester emollient may be a commercially available product such as SheaLightTM available from Lipex.
- the shea butter based ester emollient may be used in combination with other esters, silicone oils, vegetable oils, and synthetic emollients.
- Shea butter and shea butter based esters offer the potential to enhance solubility of other compounds in the moisturizing lotion composition, as well as secondary compounds.
- the increased solubility may contribute to a less greasy feel while forming a film barrier along the skin, which may limit transepidermal water loss from the skin.
- the increased solubility may provide better mixing with applied secondary compounds, which may facilitate entrapment or suspension of the secondary compounds within a particular volume of the moisturizing lotion compound.
- the moisturizing lotion composition is used to enhance the antimicrobial efficacy of one or more secondary compounds applied to the skin
- inclusion of shea butter or shea butter based ester may cause the secondary compounds (e.g., hand sanitizer, etc.) to evaporate at a slower rate, thereby extending the period of time the hand sanitizer remains active on the skin.
- Embodiments of the moisturizing lotion composition can include a cationic low humidity humectant such hydroxypropyl Bis-hydroxyethyldimonium chloride (Cola® moist 200), which can also aid in moisturizing.
- the cationic low humidity humectant e.g., the hydroxypropyl Bis-hydroxyethyldimonium chloride
- Embodiments of the moisturizing lotion composition can include a willow bark extract such as salix nigra willow bark extract.
- the willow bark extract e.g., the salix nigra willow bark extract
- Willow bark extract includes salicylic acid, which is an anti-inflammatory agent. Additionally, willow bark extract may provide moisturizing, cleansing, bactericidal, viralcidal, and skin toning benefits. Thus, in embodiments where the moisturizing lotion composition is used to enhance the antimicrobial efficacy of one or more secondary compounds applied to the skin, the salicylic acid in the willow bark extract may work together with the panthenol and the aloe vera to further sooth skin irritation, and further increase the antimicrobial efficacy of such secondary compounds in the manner previously described. In addition, the willow bark extract may increase the antimicrobial properties of the moisturizing lotion composition without the addition or use of a secondary compound. Still further, the willow bark extract offers potential analgesic (e.g., pain relieving) benefits alone and when used in combination with one or more secondary compounds as disclosed herein.
- analgesic e.g., pain relieving
- Embodiments of the moisturizing lotion composition can include an alpha hydroxyl acid such as citric acid.
- the alpha hydroxyl acid e.g., the citric acid
- the concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 0.05 wt % to about 0.20 wt %, alternatively ranging from about 0.07 wt % to about 0.15 wt %, and alternatively ranging from about 0.09 wt % to about 0.13 wt %.
- the alpha hydroxyl acid can be used to adjust the PH of the moisturizing lotion composition, and further, can be used as a chelating agent to bind metals within the composition and enhance the solubility of the metals. Citric acid also offers the potential to promote skin exfoliation and regeneration.
- Embodiments of the moisturizing lotion composition can include lipids or monoglycerides such as glyceryl stearate.
- the lipids or monoglycerides e.g., the glyceryl stearate
- the lipids or monoglycerides comprises Glyceryl Stearate SE, which is self-emulsifying and contains sodium stearate and/or potassium stearate.
- Glyceryl Stearate SE may also be used as a surfactant to enhance mixing of the moisturizing lotion composition and one or more secondary compounds added to the skin (e.g., alcohol, ethanol, vinegar, bleach, or hand sanitizer), thereby providing enhanced dispersion of secondary compounds (e.g., antimicrobial agents) throughout an applied film layer.
- Embodiments of the moisturizing lotion composition can include one or more anti-oxidant agent.
- suitable anti-oxidant agents include, without limitation, Vitamin A, Vitamin C, Vitamin D, Vitamin E, Vitamin E tocopherol acetate beta-carotene, selenium, and zinc.
- the antioxidants have a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 0.01 wt % to about 5 wt %.
- Embodiments of the moisturizing lotion composition can include one or more antimicrobial compounds with antifungal and/or antibacterial properties.
- suitable compounds with antifungal and/or antibacterial properties include Germall® Plus and Liquid Germall® Plus, each of which includes preservative diazolidinyl urea and iodopropynyl butylcarbamate in propylene glycol.
- the Liquid Germall® Plus has a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 0.15 wt % to about 0.60 wt %, alternatively ranging from about 0.22 wt % to about 0.45 wt %, and alternatively ranging from about 0.27 wt % to about 0.38 wt %.
- the Liquid Germall® Plus provides diazolidinyl urea at a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 0.14 wt % to about 0.55 wt %, and provides iodopropynyl butylcarbamate at a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 0.01 wt % to about 0.05 wt %.
- the moisturizing lotion composition may itself exhibit some antimicrobial properties without the addition of a secondary compound (e.g., alcohol, ethanol, vinegar, bleach, hand sanitizer, etc.).
- Embodiments of the moisturizing lotion composition can include a long chain organic alcohol such as cetyl alcohol.
- the long chain organic alcohol e.g., cetyl alcohol
- the long chain organic alcohol has a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 0.25 wt % to about 1.00 wt %, alternatively ranging from about 0.37 wt % to about 0.75 wt %, and alternatively ranging from about 0.45 wt % to about 0.63 wt %.
- a long chain organic alcohol such as cetyl alcohol provides emulsion stabilization, viscosity control, and antimicrobial properties.
- Embodiments of the moisturizing lotion composition can include one or more surfactants and emulsion agents such as polysorbate-20.
- the surfactant(s) and emulsion agent(s) e.g., the polysorbate-20
- the concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 0.25 wt % to about 1.00 wt %, alternatively ranging from about 0.37 wt % to about 0.75 wt %, and alternatively ranging from about 0.45 wt % to about 0.63 wt %.
- the surfactants and emulsion agents reduce the surface tension between the moisturizing lotion composition and any secondary compounds added to the skin (e.g., alcohol, ethanol, vinegar, bleach, hand sanitizer, etc.), thereby allowing more complete mixing therebetween and enhanced dispersion of antimicrobial agents throughout an applied film layer.
- any secondary compounds added to the skin e.g., alcohol, ethanol, vinegar, bleach, hand sanitizer, etc.
- the ingredients of the moisturizing lotion composition are mixed in a solvent, and in particular water, to form an aqueous solution.
- the water can be deionized water, distilled water, or combinations thereof.
- water is in the form of a water-based gel or foam.
- the water generally defines the balance of the moisturizing lotion composition.
- the water has a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 30 wt % to about 90 wt %, alternatively ranging from about 40 wt % to about 85 wt %, and alternatively ranging from about 58 wt % to about 80 wt %.
- the moisturizing lotion composition can also include one or more preservatives.
- suitable preservatives include Liquid GermallTM Plus, which can also function as an antimicrobial as previously described.
- the preservative(s) has a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 0.01 wt % to about 4.0 wt %, and alternatively from 0.10 wt % to about 1.5 wt %.
- the preservative(s) aid in stabilizing the moisturizing lotion composition.
- embodiments of moisturizing lotion compositions disclosed herein can be applied in a variety of suitable manners and to treat a variety of conditions and symptoms.
- embodiments of the moisturizing lotion composition can be dispensed by an atomizer, pump spray, or propellant based fluid, gel, or foam dispenser.
- the moisturizing lotion compositions can be applied to the face (e.g., prior to make-up application) to hydrate the skin, prevent pore clogging, treat acne, or reduce inflammation from acne on the face.
- the moisturizing lotion compositions can be applied other parts of the body (e.g., the trunk) for the foregoing benefits.
- moisturizing lotion compositions can be used as a skin pre-treatment for application to the skin prior to applying a subsequent medical treatment and/or compound thereto.
- the hydration of the skin by embodiments of moisturizing lotion compositions disclosed herein may act to make the skin more permeable to dermal or transdermal medical applications following the use of the moisturizing lotion composition.
- the moisturizing lotion compositions can be applied concurrently (e.g., mixed with) other medical compounds, thereby acting directly as a dermal or transdermal delivery agent.
- two or more of the compounds in embodiments of moisturizing lotion compositions described herein may work together to produce beneficial synergistic effects. Without being limited by this or any particular theory, it is believed such synergistic effects may depend on or result from the relative concentrations of such two or more compounds. More specifically, in embodiments of moisturizing lotion compositions disclosed herein, the ratio of the concentration of aloe vera in the moisturizing lotion composition to the concentration of vervain extract in the moisturizing lotion composition ranges from 0.80 to 1.20, alternatively ranges from 0.90 to 1.10, alternatively ranges from 0.95 to 1.05, and alternatively is 1.0.
- the ratio of the concentration of propylene glycol in the moisturizing lotion composition to the concentration of panthenol in the moisturizing lotion composition ranges from 40.0 to 60.0, alternatively ranges from 45.0 to 55.0, and alternatively is 50.0.
- the ratio of the concentration of panthenol in the moisturizing lotion composition to the concentration of chamomilla recutita extract in the moisturizing lotion composition ranges from 3.0 to 7.0, alternatively ranges from 4.0 to 6.0, alternatively ranges from 4.5 to 5.5, and alternatively is 5.0.
- the ratio of the concentration of propylene glycol in the moisturizing lotion composition to the concentration of chamomilla recutita extract in the moisturizing lotion composition ranges from 200.0 to 300.0, alternatively ranges from 225.0 to 275.0, and alternatively is 250.0.
- the ratio of the concentration of chamomilla recutita extract in the moisturizing lotion composition to the concentration of willow bark extract in the moisturizing lotion composition ranges from 0.80 to 1.20, alternatively ranges from 0.90 to 1.10, alternatively ranges from 0.95 to 1.05, and alternatively is 1.0.
- the ratio of the concentration of chamomilla recutita extract in the moisturizing lotion composition to the concentration of argan oil in the moisturizing lotion composition ranges from 1.0 to 3.0, alternatively ranges from 1.5 to 2.5, alternatively 2.0.
- the moisturizing lotion composition is used on skin to enhance the antimicrobial efficacy of one or more secondary compounds that are also applied to the skin.
- secondary compounds exhibiting antimicrobial properties include, without limitation, hand sanitizer, alcohol, vinegar, bleach (e.g., sodium hypochlorite), mixtures thereof, as well as compounds known in the art as having antimicrobial properties.
- a secondary compound includes alcohol (e.g., isopropyl alcohol, ethanol, ethyl alcohol, etc.) having a concentration (expressed as a wt % of the secondary compound) ranging from about 40 wt % to about 100 wt %, alternatively from about 50 wt % to about 90 wt %, and alternatively from about 60 wt % to about 80 wt %.
- alcohol e.g., isopropyl alcohol, ethanol, ethyl alcohol, etc.
- concentration expressed as a wt % of the secondary compound
- a secondary compound includes vinegar at a concentration (expressed as a wt % of the secondary compound) ranging from about 0.5 wt % to about 50 wt %, alternatively from about 2 wt % to about 70 wt %, and alternatively from about 5 wt % to about 100 wt %.
- a secondary compound includes bleach at a concentration (expressed as a wt % of the secondary compound) ranging from about 0.5 wt % to about 5 wt %, alternatively from about 5 wt % to about 60 wt %, and alternatively from about 10 wt % to about 100 wt %.
- the moisturizing lotion composition can be applied to the skin before the secondary compound(s) to form an initial base layer.
- the base layer may then be allowed to dry on the skin.
- the base layer may be allowed to dry for a period of time ranging from about 5 seconds to 1 minute, alternatively 15 seconds to about 5 minutes, and alternatively from about 30 seconds to 10 minutes. In other embodiments, no base layer drying time is provided.
- one or more secondary compounds may be applied to the skin.
- the moisturizing lotion composition protects the skin (e.g., forms a physical barrier) and/or enhances the resistance of the skin to the potentially negative impacts associated with the secondary compounds such as inflammation of the skin, irritation, and drying of the skin. Further, the moisturizing lotion composition may extend the period of time the secondary compound is effective for antimicrobial uses. For example, alcohol contained within hand sanitizer may evaporate at a slower rate when at least partially mixed with moisturizing lotion compositions described herein.
- the one or more secondary compounds are applied before application of the moisturizing lotion composition, the one or more secondary compounds are applied concurrently with the moisturizing lotion composition, or a combination thereof (before and during application of the moisturizing lotion composition).
- the one or more secondary compounds may be provided premixed with the moisturizing lotion composition.
- some embodiments of the moisturizing lotion composition described herein exhibit antimicrobial properties without the addition or use of a secondary compound.
- Embodiments of the moisturizing lotion composition described herein can be used in connection with a lavage procedure in which the one or more secondary compounds are employed as an aqueous flush solution.
- the moisturizing lotion composition may be applied to the nasal tissues, and a lavage solution including the one or more secondary compounds such as vinegar and/or alcohol may be used to flush particles from the nasal tissues.
- moisturizing lotion compositions disclosed herein include one or more of the following: skin conditioning agent(s), aloe vera, algae extract, vervain extract, an anti-inflammatory agent, cationic polymer(s), film forming barrier(s), emollient(s), cationic low humidity humectant(s), willow bark extract, antifungal and/or antibacterial compound(s), cetyl alcohol, surfactant(s) and/or emulsion agent(s), anti-wrinkle agent(s), skin conditioning agent(s), alpha hydroxyl acid(s), lipid(s) and/or monoglyceride(s), and anti-oxidant agent(s).
- Table 1 The formulation of one exemplary embodiment of a moisturizing lotion composition in accordance with the principles described herein is provided in Table 1 below.
- Embodiments of moisturizing lotion compositions disclosed herein were used to treat skin conditions including eczema, herpes zoster, fibromyalgia, neuropathy, and pain in human patients over a period of time.
- the symptoms experienced by each patient were identified, and the effectiveness of the treatments based on patient feedback were tracked on a weekly basis.
- the patients rated the effectiveness of the treatments on a scale—Effective (“E”), Somewhat Effective (“S”), Neutral (“N”), or Ineffective (“I”) (listed in order of decreasing effectiveness with Effective being the highest degree of effectiveness and Ineffective being the lowest degree of effectiveness).
- each patient treated indicated Effective treatment of the condition and associated symptoms was experienced, and in particular, indicated Effective treatment was experienced relatively quickly or immediately within the first week of treatment.
- all but one of the patients treated indicated the treatments were Effective over the entire duration of the treatments.
- Patient Nos. 1, 4, 5, 8, 13, and 14 indicated treatments were Effective over a period of at least 8 weeks.
- each patient listed in Table 1 indicated onset of benefit(s) (e.g., pain relief) within five (5) minutes of application of the moisturizing lotion composition, and further, each patient listed in Table 1 indicated such benefits lasted at least 7 hours after application, and more generally between 7 and 72 hours after application depending on the particular condition and level of pain.
- patient number 7 indicated complete healing of radiation burns following two weeks of treatments with the moisturizing lotion composition, which is significantly less than the period of time typically expected to fully heal radiation burns via conventional treatments with steroid creams (about four months), which at least suggests the moisturizing lotion composition improved rate of healing of the radiation burn by as much as eight times (8 ⁇ ) as compared to a conventional treatment.
Abstract
A moisturizing lotion composition includes water and propylene glycol having a concentration of 21.0 to 37.5 wt % of the moisturizing lotion composition. In addition, the moisturizing lotion composition includes aloe vera having a concentration of 0.50 to 4.0 wt % of the moisturizing lotion composition, and vervain extract having a concentration of 0.50 to 4.0 wt % of the moisturizing lotion composition. In addition, the moisturizing lotion composition includes willow bark extract having a concentration of 0.50 to 0.20 wt % of the moisturizing lotion composition. Further, the moisturizing lotion composition includes chamomilla recutita extract having a concentration of 0.05 to 0.40 wt % of the moisturizing lotion composition, wherein a ratio of the concentration of the propylene glycol to the concentration of the chamomilla recutita extract is between 4.5 and 5.5.
Description
- The present application is a continuation of U.S. nonprovisional patent application Ser. No. 17/010,123 filed Sep. 2, 2020, entitled “Enhanced Moisturizing Lotion Compositions” which claims benefit of U.S. provisional patent application No. 62/895,037 filed Sep. 3, 2019, entitled “Enhanced Moisturizing Lotion Compositions” and U.S. provisional patent application No. 62/994,155 filed Mar. 24, 2020, entitled “Enhanced Moisturizing Lotion Compositions,” all of which are hereby incorporated herein by reference in their entirety for all purposes.
- Not applicable.
- Embodiments disclosed herein relate generally to topical moisturizing lotions. More specifically, embodiments disclosed herein relate to topical moisturizing lotions for treating skin irritation, inflammation, and discomfort.
- Many individual suffer from chronic or acute skin irritation, inflammation, or discomfort. Such symptoms may be due to a variety of causes including preexisting skin disorders or diseases (e.g., eczema), exposure to a particular substance (e.g., a poisonous compound, certain chemicals in beauty products, poison ivy, etc.), insect bites, etc. The spectrum of resulting symptoms can as minor as some localized redness to extreme pain and discomfort.
- An embodiment of a moisturizing lotion composition comprises water, propylene glycol having a concentration of 21.0 to 37.5 wt % of the moisturizing lotion composition,
- aloe vera having a concentration of 0.50 to 4.0 wt % of the moisturizing lotion composition, vervain extract having a concentration of 0.50 to 4.0 wt % of the moisturizing lotion composition, willow bark extract having a concentration of 0.50 to 0.20 wt % of the moisturizing lotion composition, and chamomilla recutita extract having a concentration of 0.05 to 0.40 wt % of the moisturizing lotion composition, wherein a ratio of the concentration of the propylene glycol to the concentration of the chamomilla recutita extract is between 4.5 and 5.5. In some embodiments, the moisturizing lotion comprises argan oil having a concentration of 0.02 to 0.30 wt % of the moisturizing lotion composition. In some embodiments, the moisturizing lotion comprises an algae extract having a concentration of 1.5 to 3.0 wt % of the moisturizing lotion composition. In certain embodiments, the moisturizing lotion comprises panthenol having a concentration of 0.25 to 2.0 wt % of the moisturizing lotion composition. In certain embodiments, the water is de-ionized water having a concentration of 40 to 85 wt % of the moisturizing lotion composition. In some embodiments, the concentration of the propylene glycol is 22.5 wt % to 31.3 wt %. In some embodiments, the concentration of the aloe vera is 0.9 to 1.25 wt %. In certain embodiments, the concentration of the chamomilla recutita extract is 0.09 to 0.13 wt % of the moisturizing lotion composition. In certain embodiments, a ratio of the concentration of the aloe vera to the concentration of the vervain extract is between 0.90 and 1.10. In certain embodiments, the moisturizing lotion comprises a secondary compound including alcohol having a concentration of 40 to 100 wt % of the secondary compound.
- An embodiment of a moisturizing lotion composition comprises de-ionized water, propylene glycol having a concentration of 12.5 to 50.0 wt % of the moisturizing lotion composition, aloe vera having a concentration of 0.5 to 2.0 wt % of the moisturizing lotion composition, vervain extract having a concentration of 0.50 to 4.0 wt % of the moisturizing lotion composition, chamomilla recutita extract having a concentration of 0.07 to 1.5 wt % of the moisturizing lotion composition, and panthenol having a concentration of 0.25 to 2.0 wt % of the moisturizing lotion composition, and willow bark extract having a concentration of 0.09 to 0.13 wt % of the moisturizing lotion composition, wherein a ratio of the concentration of the propylene glycol to the concentration of the chamomilla recutita extract is between 4.5 and 5.5, wherein a ratio of the concentration of the propylene glycol to the concentration of the panthenol is between 45.0 and 55.0. In some embodiments, the moisturizing lotion comprises an antimicrobial compound. In some embodiments, the antimicrobial compound comprises diazolidinyl urea having a concentration of 0.14 to 0.55 wt % of the moisturizing lotion composition, or iodopropynyl butylcarbamate having a concentration 0.01 to 0.05 wt % of the moisturizing lotion composition. In certain embodiments, the moisturizing lotion comprises a secondary compound including alcohol having a concentration of 40 to 100 wt % of the secondary compound. In certain embodiments, a ratio of the concentration of the chamomilla recutita extract to the concentration of the willow bark extract is between 0.80 and 1.20. In some embodiments, the moisturizing lotion comprises argan oil having a concentration of 0.04 to 0.07 wt % of the moisturizing lotion composition, wherein a ratio of the concentration of the Chamomilla recutita extract to the concentration of the argan oil is between 1.5 and 2.5. In some embodiments, a ratio of the concentration of the panthenol to the concentration of the chamomilla recutita extract is between 4.0 and 6.0.
- Embodiments described herein comprise a combination of features and characteristics intended to address various shortcomings associated with certain prior compositions and methods. The foregoing has outlined rather broadly the features and technical characteristics of the disclosed embodiments in order that the detailed description that follows may be better understood. The various characteristics and features described above, as well as others, will be readily apparent to those skilled in the art upon reading the following detailed description and examples. It should be appreciated that the conception and the specific embodiments disclosed may be readily utilized as a basis for modifying or designing other compositions and methods for carrying out the same purposes as the disclosed embodiments. It should also be realized that such equivalent constructions do not depart from the spirit and scope of the principles disclosed herein.
- The following discussion is directed to various exemplary embodiments. However, one of ordinary skill in the art will understand that the examples disclosed herein have broad application, and that the discussion of any embodiment is meant only to be exemplary of that embodiment, and not intended to suggest that the scope of the disclosure, including the claims, is limited to that embodiment.
- Certain terms are used throughout the following description and claims to refer to particular features or components. As one skilled in the art will appreciate, different persons may refer to the same feature or component by different names. This document does not intend to distinguish between components or features that differ in name but not function.
- In the following discussion and in the claims, the terms “including” and “comprising” are used in an open-ended fashion, and thus should be interpreted to mean “including, but not limited to . . . ” In addition, as used herein “applying” may include any method of introducing a composition or substance into contact with the skin, such as by being rubbed, poured, sprinkled, sprayed, or combinations thereof. Further, as used herein, a “cosmetic use” includes any use intended to improve the aesthetic appearance of the skin, such as by cleansing, beautifying, promoting attractiveness, or combinations thereof. A cosmetic benefit is typically visual or aesthetic, and can be evaluated using subjective and/or objective assays known in the art. As used herein, a “dermopharmaceutical use” includes uses intended for the treatment, mitigation or prevention of a disease or disorder of the skin, and/or intended to affect the structure or a function of the skin. A dermopharmaceutical use typically has a physiological, pharmacological, and/or therapeutic effect on the skin. A dermopharmaceutical use may result in an improved aesthetic appearance of the skin by virtue of its physiological, pharmacological, or therapeutic effects. A dermopharmaceutical benefit can be evaluated using subjective and/or objective assays known in the art. As used herein, an “antimicrobial use” is a use that targets, kills, inactivates, or slows the growth of microorganisms, and thus is defined broadly herein to include antibiotic uses, antibacterial uses, antiviral uses, and antiseptics uses. In general, antibiotic uses are those that target and/or kill bacteria, fungi, parasites, or combinations thereof. Antibacterial uses are those that target and/or kill bacterial cells, and may rely on a bacteriocidal that deteriorates the integrity of cell walls and/or a bacteriostatic that inhibits the growth and/or reproduction of bacterial cells. Antiviral uses are those that kill viruses, inhibit the growth of viruses, or otherwise target viruses. Antiseptics are substances typically used on bodily tissues (e.g., skin) to reduce the possibility of infections, sepsis, or putrefaction, and are generally distinguished from antibiotics, which are internally transportable via the lymphatic system within the body. Thus, antimicrobial uses may include the use of compounds usable outside of the body only (e.g., on the face or hands), uses within the body (e.g., within the nasal passages, mucous membranes), and uses that may or may not involve compounds transportable via the lymphatic system. As described in more detail below, coronaviruses are a group of related viruses defined broadly to include, for example: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), cause of Coronavirus Disease 2019 (COVID-19); Severe Acute Respiratory Syndrome virus (SARS-CoV), cause of Severe Acute Respiratory Syndrome (SARS); and Middle East Respiratory Syndrome Coronavirus (MERS-CoV), cause of the Middle East Respiratory Syndrome (MERS), and Human Coronaviruses (HCoVs)]. It should be appreciated that recent research suggests that coronaviruses, including SARS-CoV-2, SARS-CoV, MERS-CoV, and HCoVs can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days, but can be efficiently inactivated within one minute in response to contact with surface disinfectant comprising, for example, 62% to 71% ethanol, 0.5% hydrogen peroxide or 0.1% sodium hypochlorite, as described for example in Persistence of Coronaviruses on Inanimate Surfaces and Their Inactivation With Biocidal Agents by G. Kampf et al. Journal of Hospital Infection, Volume 104, Issue 3, March 2020, Pages 246-251, which is hereby incorporated herein by reference in its entirety. As used herein, a “dermal delivery” refers to a process of mass transport of active ingredients applied on the skin to various skin strata. In comparison, as used herein a “transdermal delivery” refers to the entire process of mass transport of substances applied on the skin surface and includes their absorption by each skin strata, the strata's uptake by microcirculation, and the further distribution in the outer systemic circulation to at least a minor degree. As used herein, the term “antimicrobial” refers to an agent that kills or prohibits the growth of microorganisms such as bacteria, fungals, viruses, and parasites. Thus, antimicrobials include antibacterials (e.g., bactericides), antivirals, antiparasitics, and antifungals.
- As used herein, the terms “approximately,” “about,” “substantially,” and the like mean within 10% (i.e., plus or minus 10%) of the recited value. Unless the context dictates the contrary, all ranges set forth herein should be interpreted as being inclusive of their endpoints, and open-ended ranges should be interpreted to include only commercially practical values. Similarly, all lists of values should be considered as inclusive of intermediate values unless the context indicates the contrary.
- Embodiments of compositions and methods for using same as disclosed herein may be used for cosmetic uses, dermopharmaceutical uses, antimicrobial uses, or combinations thereof. Such compositions may generally be referred to herein as “moisturizing lotion compositions,” which can be used to treat the skin, protect the skin, improve the condition of the skin, improve the aesthetic appearance of skin, or combinations thereof.
- In general, embodiments of compositions disclosed herein (e.g., moisturizing lotion compositions) may be suitable for use on skin to moisturize, hydrate, reduce inflammation, reduce irritation, reduce pain, or combinations thereof. For example, the properties of embodiments of moisturizing lotion compositions disclosed herein may be particularly beneficial for treating eczema, psoriasis, rosacea, or dermatitis including: contact dermatitis, photo dermatitis, seborrheic dermatitis, nummular dermatitis, stasis dermatitis, dermatitis herpetiformis, atopic dermatitis, and allergic dermatitis. According to some embodiments, the moisturizing lotion compositions disclosed herein is suitable for treating diabetic neuropathy and reducing nerve pain of the skin. For example, some embodiments of compositions disclosed herein contain combinations of compounds that exhibit analgesic (e.g., pain relieving) benefits that are enhanced by a dermal or transdermal delivery behavior of the compositions, which offers the potential to increase the degree of pain relief and/or reduce the time to achieve such pain relief. In some testing described in more detail below, the onset of pain relief following application of embodiments of moisturizing lotions described herein resulted in less than 5 minutes of application. In addition, the moisturizing and/or hydration properties of some embodiments of compositions disclosed herein offer the potential to reduce sagging, reduce scarring, reduce age spots, reduce wrinkles, or combinations thereof. Similarly, some embodiments of compositions disclosed herein may be beneficial for treating skin damage and/or irritation associated with chafing, sunburn, sensitive skin, dry skin, rough skin, flaky skin, red skin, irritated skin, and itchy skin. In other instances, the anti-inflammatory properties of embodiments disclosed herein may improve acne, blisters, rash, or hives.
- Embodiments of moisturizing lotion compositions will now be described. Such moisturizing lotion compositions include a plurality of compounds or ingredients that are uniformly and homogeneously blended together to offer potential for synergistic benefits in treating the skin. More specifically, embodiments of moisturizing lotion compositions disclosed herein include one or more of the following: skin conditioning agent(s), aloe vera, algae extract, vervain extract, an anti-inflammatory agent, cationic polymer(s), film forming barrier(s), emollient(s), cationic low humidity humectant(s), willow bark extract, antifungal and/or antibacterial compound(s), cetyl alcohol, surfactant(s) and/or emulsion agent(s), anti-wrinkle agent(s), alpha hydroxyl acid(s), lipid(s) and/or monoglyceride(s), and anti-oxidant agent(s). One or more of the foregoing ingredients are mixed in a solvent, and in particular water, to form an aqueous solution. In some embodiments, a fragrance may also be added.
- Embodiments of the moisturizing lotion composition can include a variety of types of skin conditioning agents including, without limitation, propylene glycol. In such embodiments, the propylene glycol has a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 12.5 wt % to about 40.0 wt %, alternatively ranging from about 18.7 wt % to about 37.5 wt % of the moisturizing lotion composition, alternatively ranging from about 21.0 wt % to 37.5 wt % of the moisturizing lotion composition, and alternatively from about 22.5% to about 31.3% wt % of the moisturizing lotion composition. The skin conditioning agent (e.g., propylene glycol) acts as a dermal and/or transdermal delivery agent, thereby assisting with and facilitating penetration of the skin.
- Other skin conditioning agent(s) such as chamomilla recutita extract may be used alone or in combination with propylene glycol. In such embodiments, the Chamomilla recutita extract has a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 0.05 wt % to about 0.40 wt %, alternatively ranging from about 0.07 wt % to about 0.15 wt %, and alternatively ranging from about 0.09 wt % to about 0.13 wt %.
- Chamomilla recutita extract functions as a skin conditioning agent by moisturizing the skin and restoring suppleness. In addition, chamomilla recutita extract is an antioxidant that protects skin from free-radical damage.
- Chamomilla recutita extract also provides antiseptic and anti-inflammatory properties. Such properties can aid in fading spots on the skin, eliminating scars, and treating acne. In addition, chamomilla recutita extract can provide analgesic (e.g., pain relieving) benefits as described in Clinical Evaluation of Fluid Extract of Chamomilla recutita for Oral Aphthae, M. Ramos et al., Journal of Drugs Dermatol. 2006; 5(7):612-617, which is hereby incorporated herein by reference in its entirety. Further, flavinoids in chamomilla recutita extract can sooth and calm the skin, and offer the potential to improve the speed at which damaged skin heals. Accordingly, chamomilla recutita extract may be particularly beneficial in treating dry skin, eczema, psoriasis, and skin irritation. Chamomilla recutita extract may also be particularly beneficial for with particularly sensitive skin as it is anti-irritating, non-comedogenic, and hypoallergenic.
- In embodiments described in more detail below where the moisturizing lotion composition is used to enhance the antimicrobial efficacy of secondary compounds applied to the skin, the chamomilla recutita extract may work in combination with the panthenol, aloe vera, and salicylic acid to further sooth skin irritation and further increase the antimicrobial efficacy of such secondary compounds.
- Embodiments of the moisturizing lotion composition can include aloe vera such as aloe barbadensis, aloe barbadensis leaf juice, aloe vera gel, aloe vera extract, or combinations thereof. In such embodiments, the aloe vera has a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 0.50 wt % to about 4.00 wt %, alternatively ranging from about 0.75 wt % to about 1.50 wt %, and alternatively ranging from about 0.90 wt % to about 1.25 wt %.
- The aloe vera is an anti-inflammatory and provides analgesic (i.e., pain relieving) effects. The aloe vera also provides skin calming (soothing and cooling), moisturizing, and anti-wrinkle properties. Consequently, aloe vera may be particularly beneficial for treating burns, eczema, and related irritation and pain. Such benefits may be enhanced by improved dermal and/or transdermal delivery properties of the moisturizing lotion composition.
- In embodiments described in more detail below in which the moisturizing lotion composition is used to enhance the antimicrobial efficacy of one or more secondary compounds applied to the skin, the aloe vera may sooth or otherwise mitigate skin irritation, thereby allowing higher concentrations of antimicrobial agents to be applied to sensitive skin areas as compared to skin that has not been treated with the moisturizing lotion composition. Thus, for instance, application of the moisturizing lotion composition may enable hand sanitizers with higher concentrations of alcohol to be applied to skin, face, or nasal passages when the moisturizing lotion composition is applied to such areas in combination with the sanitizer (e.g., before, simultaneous with, or after application of the sanitizer). Similarly, the aloe vera prolong the period of time the skin can be exposed to such secondary compounds. As a result, the enhancements to the antimicrobial efficacy of such secondary compounds provided by aloe vera may be two-fold, as the short term effectiveness may be increased by the higher concentrations of antimicrobial agents (e.g. alcohol, etc.), and the long term effectiveness may be increased as the antimicrobial agents may remain on the skin for a longer period of time.
- Embodiments of the moisturizing lotion composition can include algae extract derived or extracted from a variety of sources including, without limitation, freshwater algae species such as green algae, red algae, brown algae, or combinations thereof; seaweed; marine algae (e.g., kelp extracts such as alginate); cyanobacteria or “blue-green algae;” and combinations thereof. In embodiments described herein, red or brown algae extract are particularly preferred. The algae extract has a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 1.0 wt % to 8.0 wt %, alternatively ranging from about 1.5 wt % to about 3.0 wt %, and alternatively ranging from about 1.8 wt % to about 2.5 wt %.
- The algae extract functions as an antioxidant, moisturizes the skin, normalizes the moisture content of the skin, and provides suppleness, which can result in anti-aging characteristics. In addition, the algae extract provides lubrication and hydration to the skin. Algae extract is a non-irritating and noncomedogenic. Accordingly, embodiments of the moisturizing lotion compositions including algae extract offer the potential to provide improved modes and rates for hydration and lubrication, as well as delivery of other ingredients of the moisturizing lotion composition into the epidermis. The algae extract may also provide analgesic (e.g., pain relieving) benefits and/or facilitate analgesic benefits provided by other constituents of the moisturizing lotion composition.
- Embodiments of the moisturizing lotion composition can include vervain extract. In such embodiments, the vervain extract included in the moisturizing lotion composition has a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 0.50 wt % to about 4.00 wt %, alternatively ranging from about 0.75 wt % to about 1.50 wt %, and alternatively ranging from about 0.90 wt % to about 1.25 wt %.
- Vervain extract is an anti-oxidant, which may work in synergy with essential derivatives to beneficially scavenge free radicals. The vervain extract may also enhance prostaglandins, which stimulates extracellular transmission of the active ingredients of the moisturizing lotion composition. In addition, vervain extract may provide analgesic (e.g., pain relieving) benefits, as well as function as a skin conditioning agent with emollient properties. Without being limited by any theory, vervain extract is also believed to stimulate circulation as an arterial vasodilator and as a decongestive on vein flow, which may enhance the rate of dispersion of one or more of the ingredients of the moisturizing lotion composition and/or enhance the rate of pain relief.
- Embodiments of the moisturizing lotion composition can include one or more anti-inflammatory agents including, without limitation, panthenol. In embodiments including panthenol as an anti-inflammatory agent, the panthenol has a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 0.25 wt % to about 2.00 wt %, alternatively ranging from about 0.37 wt % to about 0.75 wt %, and alternatively ranging from about 0.45 wt % to about 0.63 wt %. The anti-inflamatory agent(s) such as panthenol offer the potential to reduce redness and irritation of the skin, while also supplementing the moisturizing and lubricity of the moisturizing lotion composition.
- As will be described in more detail below, in embodiments where the moisturizing lotion composition is used to enhance the antimicrobial efficacy of one or more secondary compounds applied to the skin, panthenol may work together and synergistically with the aloe vera to further sooth skin irritation and further increase the antimicrobial efficacy of such secondary compounds.
- Embodiments of the moisturizing lotion composition can include one or more cationic polymers such as guar gum, guar gum modified with hydroxyalkyl groups, guar gum modified with hydroxypropyl groups, or combinations thereof. Guar gum is commercially available as Jaguar® available from Rhodia. The hydroxyalkyl groups may include alkyl groups with any number of carbon atoms. In such embodiments, the cationic polymer(s) (e.g., guar gum) have a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 0.17 wt % to about 0.70 wt %, alternatively ranging from about 0.26 wt % to about 0.53 wt %, and alternatively ranging from about 0.31 wt % to about 0.44 wt %. Such cationic polymers offer the potential to provide protection against disruptions of the cell surface by surfactants.
- Embodiments of the moisturizing lotion composition can include one or more film forming barriers such as jojoba oil. In such embodiments, the jojoba oil has a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 0.05 wt % to about 0.20 wt %, alternatively ranging from about 0.07 wt % to about 0.15 wt %, and alternatively ranging from about 0.09 wt % to about 0.13 wt %. Film barriers such as jojoba oil offer the potential to limit moisture transfer from or through the skin. More particularly, jojoba oil may limit transepidermal water loss from the skin. In addition, jojoba oil may act as an emollient and/or be used to regulate the viscosity of the moisturizing lotion composition.
- In some embodiments, the film forming barriers may include argan oil in addition to or as an alternative to jojoba oil. In such embodiments, the argan oil has a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 0.02 wt % to about 0.30 wt %, alternatively ranging from about 0.03 wt % to about 0.08 wt %, and alternatively ranging from about 0.04 wt % to about 0.07 wt %.
- The one or more film forming layers such as jojoba oil and argan oil form a barrier layer or residue layer adjacent or proximal the skin, while one or more other compounds within the moisturizing lotion composition remain suspended above the skin in an aqueous or semi-aqueous state. Consequently, in embodiments where the moisturizing lotion composition is used to enhance the antimicrobial efficacy of one or more secondary compound(s) applied to the skin, the residue layer may form a physical barrier that reduces contact between the skin and the one or more secondary compound(s). Such buffering offers the potential to reduce irritation of the skin by the secondary compound(s), allow higher concentrations of antimicrobial agents in the secondary compound(s) to be applied to the skin, allow prolonged skin exposure times for the antimicrobial agents in the secondary compound(s), or combinations thereof. The argan oil may also act as an anti-wrinkle agent. Based on some testing, it is believed that argan oil alone or via a synergistic effect when used in combination with chamomilla recutita extract may provide an enhanced analgesic (e.g., pain relieving) benefit.
- Embodiments of the moisturizing lotion composition can include an emollient such as butyrospermum parkii (shea butter) or shea butter based esters. In such embodiments, the emollient (e.g., the shea butter or shea butter based esters) has a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 0.02 wt % to about 0.10 wt %, alternatively ranging from about 0.03 wt % to about 0.08 wt %, and alternatively ranging from about 0.04 wt % to about 0.07 wt %. A shea butter based ester emollient may be a commercially available product such as SheaLight™ available from Lipex. In some embodiments, the shea butter based ester emollient may be used in combination with other esters, silicone oils, vegetable oils, and synthetic emollients.
- Shea butter and shea butter based esters offer the potential to enhance solubility of other compounds in the moisturizing lotion composition, as well as secondary compounds. Without being limited to this or any particular theory, the increased solubility may contribute to a less greasy feel while forming a film barrier along the skin, which may limit transepidermal water loss from the skin. In addition, the increased solubility may provide better mixing with applied secondary compounds, which may facilitate entrapment or suspension of the secondary compounds within a particular volume of the moisturizing lotion compound. Thus, in embodiments where the moisturizing lotion composition is used to enhance the antimicrobial efficacy of one or more secondary compounds applied to the skin, inclusion of shea butter or shea butter based ester may cause the secondary compounds (e.g., hand sanitizer, etc.) to evaporate at a slower rate, thereby extending the period of time the hand sanitizer remains active on the skin.
- Embodiments of the moisturizing lotion composition can include a cationic low humidity humectant such hydroxypropyl Bis-hydroxyethyldimonium chloride (Cola® moist 200), which can also aid in moisturizing. In such embodiments, the cationic low humidity humectant (e.g., the hydroxypropyl Bis-hydroxyethyldimonium chloride) has a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 1.5 wt % to about 6.0 wt %, alternatively ranging from about 2.3 wt % to about 4.5 wt %, and alternatively ranging from about 2.7 wt % to about 3.8 wt %.
- Embodiments of the moisturizing lotion composition can include a willow bark extract such as salix nigra willow bark extract. In such embodiments, the willow bark extract (e.g., the salix nigra willow bark extract) has a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 0.05 wt % to about 0.20 wt %, alternatively ranging from about 0.07 wt % to about 0.15 wt %, and alternatively ranging from about 0.09 wt % to about 0.13 wt %.
- Willow bark extract includes salicylic acid, which is an anti-inflammatory agent. Additionally, willow bark extract may provide moisturizing, cleansing, bactericidal, viralcidal, and skin toning benefits. Thus, in embodiments where the moisturizing lotion composition is used to enhance the antimicrobial efficacy of one or more secondary compounds applied to the skin, the salicylic acid in the willow bark extract may work together with the panthenol and the aloe vera to further sooth skin irritation, and further increase the antimicrobial efficacy of such secondary compounds in the manner previously described. In addition, the willow bark extract may increase the antimicrobial properties of the moisturizing lotion composition without the addition or use of a secondary compound. Still further, the willow bark extract offers potential analgesic (e.g., pain relieving) benefits alone and when used in combination with one or more secondary compounds as disclosed herein.
- Embodiments of the moisturizing lotion composition can include an alpha hydroxyl acid such as citric acid. In such embodiments, the alpha hydroxyl acid (e.g., the citric acid) has a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 0.05 wt % to about 0.20 wt %, alternatively ranging from about 0.07 wt % to about 0.15 wt %, and alternatively ranging from about 0.09 wt % to about 0.13 wt %. The alpha hydroxyl acid can be used to adjust the PH of the moisturizing lotion composition, and further, can be used as a chelating agent to bind metals within the composition and enhance the solubility of the metals. Citric acid also offers the potential to promote skin exfoliation and regeneration.
- Embodiments of the moisturizing lotion composition can include lipids or monoglycerides such as glyceryl stearate. In such embodiments, the lipids or monoglycerides (e.g., the glyceryl stearate) has at a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 0.25 wt % to about 1.00 wt %, alternatively ranging from about 0.37 wt % to about 0.75 wt %, and alternatively ranging from about 0.45 wt % to about 0.63 wt %. In some embodiments, the lipids or monoglycerides comprises Glyceryl Stearate SE, which is self-emulsifying and contains sodium stearate and/or potassium stearate. In some embodiments, Glyceryl Stearate SE may also be used as a surfactant to enhance mixing of the moisturizing lotion composition and one or more secondary compounds added to the skin (e.g., alcohol, ethanol, vinegar, bleach, or hand sanitizer), thereby providing enhanced dispersion of secondary compounds (e.g., antimicrobial agents) throughout an applied film layer.
- Embodiments of the moisturizing lotion composition can include one or more anti-oxidant agent. Examples of suitable anti-oxidant agents include, without limitation, Vitamin A, Vitamin C, Vitamin D, Vitamin E, Vitamin E tocopherol acetate beta-carotene, selenium, and zinc. In such embodiments, the antioxidants have a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 0.01 wt % to about 5 wt %.
- Embodiments of the moisturizing lotion composition can include one or more antimicrobial compounds with antifungal and/or antibacterial properties. Examples of suitable compounds with antifungal and/or antibacterial properties include Germall® Plus and Liquid Germall® Plus, each of which includes preservative diazolidinyl urea and iodopropynyl butylcarbamate in propylene glycol. In such embodiments, the Liquid Germall® Plus has a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 0.15 wt % to about 0.60 wt %, alternatively ranging from about 0.22 wt % to about 0.45 wt %, and alternatively ranging from about 0.27 wt % to about 0.38 wt %. The Liquid Germall® Plus provides diazolidinyl urea at a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 0.14 wt % to about 0.55 wt %, and provides iodopropynyl butylcarbamate at a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 0.01 wt % to about 0.05 wt %. Thus, in some embodiments, the moisturizing lotion composition may itself exhibit some antimicrobial properties without the addition of a secondary compound (e.g., alcohol, ethanol, vinegar, bleach, hand sanitizer, etc.).
- Embodiments of the moisturizing lotion composition can include a long chain organic alcohol such as cetyl alcohol. In such embodiments, the long chain organic alcohol (e.g., cetyl alcohol) has a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 0.25 wt % to about 1.00 wt %, alternatively ranging from about 0.37 wt % to about 0.75 wt %, and alternatively ranging from about 0.45 wt % to about 0.63 wt %. A long chain organic alcohol such as cetyl alcohol provides emulsion stabilization, viscosity control, and antimicrobial properties.
- Embodiments of the moisturizing lotion composition can include one or more surfactants and emulsion agents such as polysorbate-20. In such embodiments, the surfactant(s) and emulsion agent(s) (e.g., the polysorbate-20) has a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 0.25 wt % to about 1.00 wt %, alternatively ranging from about 0.37 wt % to about 0.75 wt %, and alternatively ranging from about 0.45 wt % to about 0.63 wt %. The surfactants and emulsion agents reduce the surface tension between the moisturizing lotion composition and any secondary compounds added to the skin (e.g., alcohol, ethanol, vinegar, bleach, hand sanitizer, etc.), thereby allowing more complete mixing therebetween and enhanced dispersion of antimicrobial agents throughout an applied film layer.
- As previously described, the ingredients of the moisturizing lotion composition are mixed in a solvent, and in particular water, to form an aqueous solution. In general, the water can be deionized water, distilled water, or combinations thereof. In some embodiments, water is in the form of a water-based gel or foam. In embodiments described herein, the water generally defines the balance of the moisturizing lotion composition. In particular, the water has a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 30 wt % to about 90 wt %, alternatively ranging from about 40 wt % to about 85 wt %, and alternatively ranging from about 58 wt % to about 80 wt %.
- The moisturizing lotion composition can also include one or more preservatives. Examples of suitable preservatives include Liquid Germall™ Plus, which can also function as an antimicrobial as previously described. In such embodiments, the preservative(s) has a concentration (expressed as a wt % of the moisturizing lotion composition) ranging from about 0.01 wt % to about 4.0 wt %, and alternatively from 0.10 wt % to about 1.5 wt %. In general, the preservative(s) aid in stabilizing the moisturizing lotion composition.
- In general, embodiments of moisturizing lotion compositions disclosed herein can be applied in a variety of suitable manners and to treat a variety of conditions and symptoms. For example, embodiments of the moisturizing lotion composition can be dispensed by an atomizer, pump spray, or propellant based fluid, gel, or foam dispenser. In addition, the moisturizing lotion compositions can be applied to the face (e.g., prior to make-up application) to hydrate the skin, prevent pore clogging, treat acne, or reduce inflammation from acne on the face. Similarly, the moisturizing lotion compositions can be applied other parts of the body (e.g., the trunk) for the foregoing benefits. Further, moisturizing lotion compositions can be used as a skin pre-treatment for application to the skin prior to applying a subsequent medical treatment and/or compound thereto. Without being limited by this or any particular theory, the hydration of the skin by embodiments of moisturizing lotion compositions disclosed herein may act to make the skin more permeable to dermal or transdermal medical applications following the use of the moisturizing lotion composition. For example, the moisturizing lotion compositions can be applied concurrently (e.g., mixed with) other medical compounds, thereby acting directly as a dermal or transdermal delivery agent.
- Two or more of the compounds in embodiments of moisturizing lotion compositions described herein may work together to produce beneficial synergistic effects. Without being limited by this or any particular theory, it is believed such synergistic effects may depend on or result from the relative concentrations of such two or more compounds. More specifically, in embodiments of moisturizing lotion compositions disclosed herein, the ratio of the concentration of aloe vera in the moisturizing lotion composition to the concentration of vervain extract in the moisturizing lotion composition ranges from 0.80 to 1.20, alternatively ranges from 0.90 to 1.10, alternatively ranges from 0.95 to 1.05, and alternatively is 1.0. In addition, in embodiments of moisturizing lotion compositions disclosed herein including propylene glycol and panthenol, the ratio of the concentration of propylene glycol in the moisturizing lotion composition to the concentration of panthenol in the moisturizing lotion composition ranges from 40.0 to 60.0, alternatively ranges from 45.0 to 55.0, and alternatively is 50.0. Further, in embodiments of moisturizing lotion compositions disclosed herein including panthenol and chamomilla recutita extract, the ratio of the concentration of panthenol in the moisturizing lotion composition to the concentration of chamomilla recutita extract in the moisturizing lotion composition ranges from 3.0 to 7.0, alternatively ranges from 4.0 to 6.0, alternatively ranges from 4.5 to 5.5, and alternatively is 5.0. Still further, in embodiments of moisturizing lotion compositions disclosed herein including propylene glycol and chamomilla recutita extract, the ratio of the concentration of propylene glycol in the moisturizing lotion composition to the concentration of chamomilla recutita extract in the moisturizing lotion composition ranges from 200.0 to 300.0, alternatively ranges from 225.0 to 275.0, and alternatively is 250.0. In embodiments of moisturizing lotion compositions disclosed herein including chamomilla recutita extract and willow bark extract, the ratio of the concentration of chamomilla recutita extract in the moisturizing lotion composition to the concentration of willow bark extract in the moisturizing lotion composition ranges from 0.80 to 1.20, alternatively ranges from 0.90 to 1.10, alternatively ranges from 0.95 to 1.05, and alternatively is 1.0. And in embodiments of moisturizing lotion compositions disclosed herein including chamomilla recutita extract and argan oil, the ratio of the concentration of chamomilla recutita extract in the moisturizing lotion composition to the concentration of argan oil in the moisturizing lotion composition ranges from 1.0 to 3.0, alternatively ranges from 1.5 to 2.5, alternatively 2.0.
- In some embodiments, the moisturizing lotion composition is used on skin to enhance the antimicrobial efficacy of one or more secondary compounds that are also applied to the skin. Such secondary compounds exhibiting antimicrobial properties include, without limitation, hand sanitizer, alcohol, vinegar, bleach (e.g., sodium hypochlorite), mixtures thereof, as well as compounds known in the art as having antimicrobial properties. In some embodiments, a secondary compound includes alcohol (e.g., isopropyl alcohol, ethanol, ethyl alcohol, etc.) having a concentration (expressed as a wt % of the secondary compound) ranging from about 40 wt % to about 100 wt %, alternatively from about 50 wt % to about 90 wt %, and alternatively from about 60 wt % to about 80 wt %. In some embodiments, a secondary compound includes vinegar at a concentration (expressed as a wt % of the secondary compound) ranging from about 0.5 wt % to about 50 wt %, alternatively from about 2 wt % to about 70 wt %, and alternatively from about 5 wt % to about 100 wt %. In some embodiments, a secondary compound includes bleach at a concentration (expressed as a wt % of the secondary compound) ranging from about 0.5 wt % to about 5 wt %, alternatively from about 5 wt % to about 60 wt %, and alternatively from about 10 wt % to about 100 wt %.
- In embodiments where the moisturizing lotion composition is used to enhance the antimicrobial efficacy of one or more secondary compounds applied to the skin, the moisturizing lotion composition can be applied to the skin before the secondary compound(s) to form an initial base layer. The base layer may then be allowed to dry on the skin. For example, the base layer may be allowed to dry for a period of time ranging from about 5 seconds to 1 minute, alternatively 15 seconds to about 5 minutes, and alternatively from about 30 seconds to 10 minutes. In other embodiments, no base layer drying time is provided. After the application of the moisturizing lotion composition as a base layer, one or more secondary compounds may be applied to the skin. Without being limited by this or any particular theory, the moisturizing lotion composition protects the skin (e.g., forms a physical barrier) and/or enhances the resistance of the skin to the potentially negative impacts associated with the secondary compounds such as inflammation of the skin, irritation, and drying of the skin. Further, the moisturizing lotion composition may extend the period of time the secondary compound is effective for antimicrobial uses. For example, alcohol contained within hand sanitizer may evaporate at a slower rate when at least partially mixed with moisturizing lotion compositions described herein.
- In other embodiments, the one or more secondary compounds are applied before application of the moisturizing lotion composition, the one or more secondary compounds are applied concurrently with the moisturizing lotion composition, or a combination thereof (before and during application of the moisturizing lotion composition). In still other embodiments, the one or more secondary compounds may be provided premixed with the moisturizing lotion composition. In addition, as previously described, some embodiments of the moisturizing lotion composition described herein exhibit antimicrobial properties without the addition or use of a secondary compound.
- Embodiments of the moisturizing lotion composition described herein can be used in connection with a lavage procedure in which the one or more secondary compounds are employed as an aqueous flush solution. For example, the moisturizing lotion composition may be applied to the nasal tissues, and a lavage solution including the one or more secondary compounds such as vinegar and/or alcohol may be used to flush particles from the nasal tissues.
- To further illustrate various illustrative embodiments of the present disclosure, the following non-limiting examples are provided.
- As previously described, embodiments of moisturizing lotion compositions disclosed herein include one or more of the following: skin conditioning agent(s), aloe vera, algae extract, vervain extract, an anti-inflammatory agent, cationic polymer(s), film forming barrier(s), emollient(s), cationic low humidity humectant(s), willow bark extract, antifungal and/or antibacterial compound(s), cetyl alcohol, surfactant(s) and/or emulsion agent(s), anti-wrinkle agent(s), skin conditioning agent(s), alpha hydroxyl acid(s), lipid(s) and/or monoglyceride(s), and anti-oxidant agent(s). The formulation of one exemplary embodiment of a moisturizing lotion composition in accordance with the principles described herein is provided in Table 1 below.
-
TABLE 1 wt % Ingredients (of the composition) Deionized water 64.25 Propylene glycol 25.00 Cola ® moist 200 3.00 Algae extract 2.00 Aloe vera 1.00 Vervain extract 1.00 Fragrance oil 0.60 Cetyl Alcohol 0.50 Glyceryl Stearate SE 0.50 Panthenol 0.50 Polysorbate-20 0.50 Jaguar HP-8 0.35 Liquid Germall ® plus 0.30 Chamomilla recutita extract 0.10 Citric acid 0.10 Jojoba oil 0.10 Willow bark extract 0.10 Argan oil 0.05 Lipex SheaLight ™ 0.05 Total 100 - Embodiments of moisturizing lotion compositions disclosed herein were used to treat skin conditions including eczema, herpes zoster, fibromyalgia, neuropathy, and pain in human patients over a period of time. The symptoms experienced by each patient were identified, and the effectiveness of the treatments based on patient feedback were tracked on a weekly basis. The patients rated the effectiveness of the treatments on a scale—Effective (“E”), Somewhat Effective (“S”), Neutral (“N”), or Ineffective (“I”) (listed in order of decreasing effectiveness with Effective being the highest degree of effectiveness and Ineffective being the lowest degree of effectiveness). In cases where the patient previously employed a different therapy to treat the symptom, the effectiveness of the treatments with the moisturizing lotion compositions disclosed herein was evaluated in comparison to the previously employed therapy. In other words, the previously employed therapy served as a baseline against which the effectiveness of treatments with the moisturizing lotion compositions disclosed herein were compared. The results of the treatments are summarized in Table 2 below.
- As shown in Table 2 below, each patient treated indicated Effective treatment of the condition and associated symptoms was experienced, and in particular, indicated Effective treatment was experienced relatively quickly or immediately within the first week of treatment. In addition, all but one of the patients treated (Patient No. 15) indicated the treatments were Effective over the entire duration of the treatments. For example, Patient Nos. 1, 4, 5, 8, 13, and 14 indicated treatments were Effective over a period of at least 8 weeks.
- Although it is not explicitly shown in Table 1, each patient listed in Table 1 indicated onset of benefit(s) (e.g., pain relief) within five (5) minutes of application of the moisturizing lotion composition, and further, each patient listed in Table 1 indicated such benefits lasted at least 7 hours after application, and more generally between 7 and 72 hours after application depending on the particular condition and level of pain. In addition, although it is not explicitly shown in Table 1, patient number 7 indicated complete healing of radiation burns following two weeks of treatments with the moisturizing lotion composition, which is significantly less than the period of time typically expected to fully heal radiation burns via conventional treatments with steroid creams (about four months), which at least suggests the moisturizing lotion composition improved rate of healing of the radiation burn by as much as eight times (8×) as compared to a conventional treatment.
-
Weeks of Patient Symptoms Application No. Age Condition Dryness Itching Swelling Redness Pain Tingling Burning 1 2 4 8 Previous Therapies 1 46 Eczema x x x E E E E Eucrisa 2 56 Eczema x x x E E Clobetasol, Prednisone, Triamcinolone 3 87 Eczema, Herpes x x E 0.25% Dexamethasone zoster cream 4 Herpes zoster x x E E E E Valtrex 5 63 Fibromyalgia x E E E E 6 62 Irritated legs x x E E N/A 7 Radiation burn x x x E E E Vaseline 8 57 Neuropathy x x E E E E Gabapentin 9 85 Neuropathy x x E E 10 Neuropathy, Pain x E Gabapentin in neck and temples 11 64 Pain in body x E E N/A 12 Pain in both legs x E and feet 13 38 Pain in jaw and x x E E E E BC powder tooth 14 62 Pain in right leg x E E E E N/A 15 Pain siatic x E E S N CBD oil E = Effective S = Somewhat Effective N = Neutral I = Ineffective - While exemplary embodiments have been shown and described, modifications thereof can be made by one skilled in the art without departing from the scope or teachings herein. The embodiments described herein are exemplary only and are not limiting. Many variations and modifications of the systems, apparatus, and processes described herein are possible and are within the scope of the disclosure. Accordingly, the scope of protection is not limited to the embodiments described herein, but is only limited by the claims that follow, the scope of which shall include all equivalents of the subject matter of the claims. Unless expressly stated otherwise, the steps in a method claim may be performed in any order. The recitation of identifiers such as (a), (b), (c) or (1), (2), (3) before steps in a method claim are not intended to and do not specify a particular order to the steps, but rather are used to simplify subsequent reference to such steps.
Claims (17)
1. A moisturizing lotion composition, comprising:
water;
propylene glycol having a concentration of 21.0 to 37.5 wt % of the moisturizing lotion composition;
aloe vera having a concentration of 0.50 to 4.0 wt % of the moisturizing lotion composition;
vervain extract having a concentration of 0.50 to 4.0 wt % of the moisturizing lotion composition;
willow bark extract having a concentration of 0.50 to 0.20 wt % of the moisturizing lotion composition; and
chamomilla recutita extract having a concentration of 0.05 to 0.40 wt % of the moisturizing lotion composition;
wherein a ratio of the concentration of the propylene glycol to the concentration of the chamomilla recutita extract is between 4.5 and 5.5.
2. The moisturizing lotion composition of claim 1 , further comprising:
argan oil having a concentration of 0.02 to 0.30 wt % of the moisturizing lotion composition.
3. The moisturizing lotion composition of claim 2 , further comprising:
an algae extract having a concentration of 1.5 to 3.0 wt % of the moisturizing lotion composition.
4. The moisturizing lotion composition of claim 2 , further comprising:
panthenol having a concentration of 0.25 to 2.0 wt % of the moisturizing lotion composition.
5. The moisturizing lotion composition of claim 1 , wherein the water is de-ionized water having a concentration of 40 to 85 wt % of the moisturizing lotion composition.
6. The moisturizing lotion composition of claim 1 , wherein the concentration of the propylene glycol is 22.5 wt % to 31.3 wt %.
7. The moisturizing lotion composition of claim 1 , wherein the concentration of the aloe vera is 0.9 to 1.25 wt %.
8. The moisturizing lotion composition of claim 1 , wherein the concentration of the chamomilla recutita extract is 0.09 to 0.13 wt % of the moisturizing lotion composition.
9. The moisturizing lotion composition of claim 1 , wherein a ratio of the concentration of the aloe vera to the concentration of the vervain extract is between 0.90 and 1.10.
10. The moisturizing lotion composition of claim 1 , further comprising a secondary compound including alcohol having a concentration of 40 to 100 wt % of the secondary compound.
11. A moisturizing lotion composition, comprising:
de-ionized water;
propylene glycol having a concentration of 12.5 to 50.0 wt % of the moisturizing lotion composition;
aloe vera having a concentration of 0.5 to 2.0 wt % of the moisturizing lotion composition;
vervain extract having a concentration of 0.50 to 4.0 wt % of the moisturizing lotion composition;
chamomilla recutita extract having a concentration of 0.07 to 1.5 wt % of the moisturizing lotion composition; and
panthenol having a concentration of 0.25 to 2.0 wt % of the moisturizing lotion composition; and
willow bark extract having a concentration of 0.09 to 0.13 wt % of the moisturizing lotion composition;
wherein a ratio of the concentration of the propylene glycol to the concentration of the chamomilla recutita extract is between 4.5 and 5.5;
wherein a ratio of the concentration of the propylene glycol to the concentration of the panthenol is between 45.0 and 55.0.
12. The moisturizing lotion composition of claim 11 , further comprising an antimicrobial compound.
13. The moisturizing lotion composition of claim 12 , wherein the antimicrobial compound comprises:
diazolidinyl urea having a concentration of 0.14 to 0.55 wt % of the moisturizing lotion composition; or
iodopropynyl butylcarbamate having a concentration 0.01 to 0.05 wt % of the moisturizing lotion composition.
14. The moisturizing lotion composition of claim 11 , further comprising a secondary compound including alcohol having a concentration of 40 to 100 wt % of the secondary compound.
15. The moisturizing lotion composition of claim 11 , wherein a ratio of the concentration of the chamomilla recutita extract to the concentration of the willow bark extract is between 0.80 and 1.20.
16. The moisturizing lotion composition of claim 15 , further comprising argan oil having a concentration of 0.04 to 0.07 wt % of the moisturizing lotion composition, wherein a ratio of the concentration of the chamomilla recutita extract to the concentration of the argan oil is between 1.5 and 2.5.
17. The moisturizing lotion composition of claim 11 , wherein a ratio of the concentration of the panthenol to the concentration of the chamomilla recutita extract is between 4.0 and 6.0.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/122,555 US20230218541A1 (en) | 2019-09-03 | 2023-03-16 | Enhanced Moisturizing Lotion Compositions |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962895037P | 2019-09-03 | 2019-09-03 | |
US202062994155P | 2020-03-24 | 2020-03-24 | |
US17/010,123 US11633368B2 (en) | 2019-09-03 | 2020-09-02 | Enhanced moisturizing lotion compositions |
US18/122,555 US20230218541A1 (en) | 2019-09-03 | 2023-03-16 | Enhanced Moisturizing Lotion Compositions |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/010,123 Continuation US11633368B2 (en) | 2019-09-03 | 2020-09-02 | Enhanced moisturizing lotion compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230218541A1 true US20230218541A1 (en) | 2023-07-13 |
Family
ID=74682599
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/010,123 Active US11633368B2 (en) | 2019-09-03 | 2020-09-02 | Enhanced moisturizing lotion compositions |
US18/122,555 Pending US20230218541A1 (en) | 2019-09-03 | 2023-03-16 | Enhanced Moisturizing Lotion Compositions |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/010,123 Active US11633368B2 (en) | 2019-09-03 | 2020-09-02 | Enhanced moisturizing lotion compositions |
Country Status (1)
Country | Link |
---|---|
US (2) | US11633368B2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11633368B2 (en) * | 2019-09-03 | 2023-04-25 | Milton D. Moore | Enhanced moisturizing lotion compositions |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11633368B2 (en) * | 2019-09-03 | 2023-04-25 | Milton D. Moore | Enhanced moisturizing lotion compositions |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4709481A (en) | 1986-08-19 | 1987-12-01 | Moore Milton D | Shaving tool |
US4944939A (en) | 1987-12-14 | 1990-07-31 | Moore Milton D | Shaving preparation for treatment and prevention of PFB (Ingrown Hairs) |
US5387412A (en) | 1990-08-27 | 1995-02-07 | Moore; Milton D. | 1,2-propylene glycol shaving solution and method of use thereof |
US6861051B2 (en) | 2002-07-30 | 2005-03-01 | Milton D. Moore | 1,2-propylene glycol skin preparation solution and method of use thereof |
DE102006020382A1 (en) | 2006-04-28 | 2007-10-31 | Henkel Kgaa | Cosmetic oil-in-water emulsion, useful e.g. to treat skin, comprises oil or fat phase comprising a component e.g. branched saturated alkanol, water, a cosmetically active substance e.g. monomer and a polysaccharide |
US20090050170A1 (en) | 2007-08-24 | 2009-02-26 | Moore Milton D | Shaving solutions for electric shaving devices |
US20090123409A1 (en) | 2007-11-01 | 2009-05-14 | Moore Milton D | Enhanced shaving compositions |
ES2373704B1 (en) | 2010-02-18 | 2013-01-24 | Lipotec S.A. | LIPOSOMES FOR THE TREATMENT OF TEXTILE MATERIALS. |
RS59797B1 (en) | 2014-08-20 | 2020-02-28 | Samumed Llc | Gamma-diketones for treatment and prevention of aging skin and wrinkles |
JP6770968B2 (en) | 2015-03-05 | 2020-10-21 | ルブリゾル アドバンスド マテリアルズ, インコーポレイテッド | Fermented extract of Eupenicillium crustaceum and its cosmetic use |
JP2018517786A (en) | 2015-06-19 | 2018-07-05 | グローバル ヘルス ソリューションズ リミテッド ライアビリティ カンパニー | Petrolatum composition containing cationic biocide |
JP6906518B2 (en) | 2015-08-10 | 2021-07-21 | エボニック オペレーションズ ゲーエムベーハー | Skin osmotic delivery system based on a positively charged sugar emulsifier |
CN105125467A (en) * | 2015-09-30 | 2015-12-09 | 青岛海之源智能技术有限公司 | Emulsion removing red blood and preparing method of emulsion |
CN109568246A (en) * | 2018-12-24 | 2019-04-05 | 广州欧盛化妆品有限公司 | A kind of crease-resistant moisturiser and preparation method thereof |
-
2020
- 2020-09-02 US US17/010,123 patent/US11633368B2/en active Active
-
2023
- 2023-03-16 US US18/122,555 patent/US20230218541A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11633368B2 (en) * | 2019-09-03 | 2023-04-25 | Milton D. Moore | Enhanced moisturizing lotion compositions |
Also Published As
Publication number | Publication date |
---|---|
US20210059958A1 (en) | 2021-03-04 |
US11633368B2 (en) | 2023-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2011522831A (en) | Acne treatment composition containing nanosilver and use thereof | |
US20110236503A1 (en) | Topical Skincare Composition | |
KR20110074513A (en) | Topical treatment of skin infection | |
EP3713583A1 (en) | Methods and compositions for treatment of skin | |
US20080076831A1 (en) | Hemorrhoid reliever and method of use | |
US11266588B2 (en) | Skin treatment methods and compositions with retinoid and delivery systems thereof | |
US20230218541A1 (en) | Enhanced Moisturizing Lotion Compositions | |
US9717757B1 (en) | Composition and method to treat and prevent muscle cramping | |
US8513225B2 (en) | Composition and method for topical treatment of skin lesions | |
JPH027287B2 (en) | ||
JP2007332078A (en) | Agent for external use containing ozone-dissolved glycerol solution such as cosmetic, quasi-drug or medicament (pharmaceutical) | |
US20040234628A1 (en) | Topical composition for the treatment of skin disorders and methods of using the same | |
CN113347982A (en) | Dermal skin protectant and carrier | |
JP2009001575A (en) | Agent for external use containing ozone-dissolved glycerol solution such as cosmetic, quasi-drug or medicament (pharmaceutical) | |
US10912753B1 (en) | Topical skin care composition | |
US6583184B1 (en) | Compositions having comfrey and methods for reducing retinoid-induced skin irritation | |
WO2019175902A1 (en) | A topical preparation for various skin ailments | |
US20130034618A1 (en) | Compositions for treating the integument | |
AU2021103390A4 (en) | A Skincare Oil | |
WO2017197535A1 (en) | Product for the therapy and prevention of burnout syndrome of the scalp and the skin | |
US9446089B1 (en) | Oil blend for skin treatment | |
US20210386670A1 (en) | Nanoemulsion system for transdermal delivery of pharmaceutical compositions and other active agents | |
JP2017534689A (en) | Methods for the prevention and treatment of acne | |
US20130064900A1 (en) | Anti-dandruff methods, processes and compositions | |
DE202023102783U1 (en) | Composition of an antibacterial lotion with lemongrass oil enriched with bioactive substances |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |